The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I trial of weekly cabazitaxel with concurrent intensity modulated radiation therapy (IMRT) and androgen deprivation therapy (ADT) for the treatment of high-risk prostate cancer (PCa).
Jianqing Lin
No relevant relationships to disclose
Robert Benjamin Den
No relevant relationships to disclose
Timothy N Showalter
No relevant relationships to disclose
Jean H. Hoffman-Censits
No relevant relationships to disclose
Monica McGuire
No relevant relationships to disclose
Mark Hurwitz
No relevant relationships to disclose
Edouard John Trabulsi
No relevant relationships to disclose
Hushan Yang
No relevant relationships to disclose
Ruth C. Birbe
No relevant relationships to disclose
Inna Chervoneva
No relevant relationships to disclose
Adam Dicker
No relevant relationships to disclose
William Kevin Kelly
No relevant relationships to disclose